SCHEMBL1556570

SCHEMBL1556570

CS(=O)(=O)c1ccc(OCc2cccc(C3CCNCC3)n2)c(F)c1

nearest known ligand 0.40

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 8/20 0.40
HTR1A P08908 6/20 0.40
SLC6A2 P23975 6/20 0.40
SLC6A3 Q01959 5/20 0.40
HTR6 P50406 5/20 0.39
PRMT5 O14744 1/20 0.38
CCNT1 O60563 2/20 0.38
CDK9 P50750 2/20 0.38
GPR119 Q8TDV5 2/20 0.35
ALK Q9UM73 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1557130 0.84 GPR119 (0.42) GPR119
SCHEMBL1118288 0.81 GPR119 (0.46) SLC6A4HTR1ASLC6A2SLC6A3PRMT5
SCHEMBL1557797 0.80 GPR119 (0.57) GPR119
SCHEMBL1557144 0.80 GPR119 (0.55) GPR119
SCHEMBL24330383 0.80 GLP1R (0.43) HTR6GPR119
SCHEMBL29555159 0.80 GLP1R (0.43) HTR6GPR119
SCHEMBL11384759 0.80 GPR119 (0.43) GPR119
SCHEMBL3348799 0.78 SLC6A4 (0.50) SLC6A4HTR1ASLC6A2SLC6A3HTR6
Hydrochloric Acid SCHEMBL3346815 0.77 SLC6A4 (0.49) SLC6A4HTR1ASLC6A2SLC6A3HTR6
SCHEMBL31140541 0.76 SLC6A4 (0.47) SLC6A4SLC6A2SLC6A3HTR6HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120184572-A1 ARYL GPR119 AGONISTS AND USES THEREOF METABOLEX, INC. 2012-07-19 US disclosed
US-20120184572-A1 ARYL GPR119 AGONISTS AND USES THEREOF METABOLEX, INC. 2012-07-19 US disclosed
US-20120184572-A1 ARYL GPR119 AGONISTS AND USES THEREOF METABOLEX, INC. 2012-07-19 US disclosed
US-20110294836-A1 ARYL GPR119 AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2011-12-01 US disclosed
US-20110294836-A1 ARYL GPR119 AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2011-12-01 US disclosed
US-20110294836-A1 ARYL GPR119 AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2011-12-01 US disclosed
EP-2303859-A2 ARYL GPR119 AGONISTS AND USES THEREOF Metabolex Inc. (US) 2011-04-06 EP disclosed
WO-2010008739-A2 ARYL GPR119 AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-01-21 WO disclosed
WO-2010008739-A2 ARYL GPR119 AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184572-A1 ARYL GPR119 AGONISTS AND USES THEREOF GPR119, GPR27, GPR65 SLC6A4 1278/4885HTR1A 351/4885SLC6A2 1250/4885
US-20110294836-A1 ARYL GPR119 AGONISTS AND USES THEREOF GPR119, GPR27, GPR65 SLC6A4 1278/4885HTR1A 351/4885SLC6A2 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.